Physician profile
Mitchell A Jackson
NPI 1902958929
$583,900.67
in general payments reported to CMS, 2019-2025
47 companies · $56K in 2025
The $56K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $121K · 2020: $58K · 2021: $72K · 2022: $102K · 2023: $117K · 2024: $58K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $81K · Consulting Fee: $69K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $22K · Travel and Lodging: $15K · Honoraria: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $80,500.00 |
| Consulting Fee | $68,782.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,440.00 |
| Food and Beverage | $21,764.13 |
| Travel and Lodging | $14,853.20 |
| Honoraria | $14,000.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $135,332.78 | 2022-2025 | Miebo, Xiidra, Crystalens Accommodating Iol (At-52ao) |
| Oyster Point Pharma, INC. | $53,795.47 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47,070.70 | 2019-2021 | |
| Lensar, INC. | $45,163.78 | 2019-2025 | Lensar Laser System |
| Ocular Therapeutix, INC. | $34,844.52 | 2019-2025 | Dextenza |
| Allergan, INC. | $33,270.64 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $30,586.01 | 2019-2025 | Artevo 800, Visumax, Veracity Surgical |
| Sun Pharmaceutical Industries INC. | $29,766.31 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Omeros Corporation | $25,979.10 | 2019-2021 | |
| Harrow Eye, LLC | $20,518.95 | 2023-2025 | Vevye, Iheezo, Flarex |
| Novartis Pharmaceuticals Corporation | $19,645.42 | 2019-2023 | |
| Eyepoint US, INC. | $16,946.54 | 2019-2021 | |
| Sight Sciences, INC. | $14,035.12 | 2019-2024 | Tearcare System |
| Abbvie INC. | $12,188.96 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $10,974.59 | 2019-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $7,704.97 | 2020-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Shire North American Group INC | $6,859.86 | 2019 | |
| Dompe US, INC. | $5,478.31 | 2019-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $5,169.81 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $4,032.61 | 2019-2025 | Catalys System |
| Glaukos Corporation | $4,031.56 | 2019-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Idose |
| Tearlab Corp | $3,737.95 | 2019-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Oculus, INC. | $3,341.24 | 2019-2025 | Na |
| Quidel Corporation | $3,053.41 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $1,802.24 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Seagen INC. | $1,800.00 | 2022 | |
| Optos, INC. | $1,500.00 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope |
| Carl Zeiss Meditec USA, INC. | $1,308.34 | 2021-2023 | Artevo 800, Quatera 700 |
| Alcon Vision LLC | $1,087.19 | 2019-2025 | Clareon, Clareon Panoptix Pro, Simbrinza |
| Tarsus Pharmaceuticals, INC. | $961.31 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $473.93 | 2022-2025 | Streamline, Clearpath, Kahook Dual Blade |
| Microsurgical Technology, INC. | $400.78 | 2025 | |
| Staar Surgical Company | $226.59 | 2019 | |
| Ivantis, INC | $173.65 | 2019-2021 | |
| Biotissue Holdings INC. | $124.63 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.97 | 2021 | |
| Bausch Health US, LLC | $102.44 | 2019-2020 | |
| Thea Pharma INC. | $67.14 | 2022-2023 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $60.68 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $53.06 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $31.62 | 2022-2023 | Tepezza |
| Avedro INC. | $29.22 | 2019 | |
| Beaver-Visitec International, INC. | $24.79 | 2023 | |
| Amgen INC. | $21.50 | 2024 | Tepezza |
| Terumo Medical Corporation | $18.98 | 2024 | Azur Cx Detachable |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,833.10 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.